By targeting immunoglobulin E (IgE), thymic stromal lymphopoietin (TSLP), and specific cytokines such as IL-5, IL-4, and IL-13, biologics offer more precise and personalized treatment in patients with severe asthma and associated comorbidities [33]. The gene discussed is TSLP; the disease is asthma.